Randox Presents Latest Diagnostics and Quality Control Solutions at WHX Labs Dubai
Posted on 10 Feb 2026
At WHX Labs Dubai 2026, Randox Laboratories (Crumlin, UK) showcased its broad, multi-disciplinary diagnostics portfolio at Booth S2.B10. The company presented its integrated range of reagents, analyzers, and quality control solutions designed to support clinical laboratories, hospitals, and point-of-care testing environments worldwide.
A key highlight was the Vivalytic platform, a fully automated, all-in-one molecular diagnostics system developed in collaboration with Bosch. Vivalytic integrates extraction, amplification, and detection within a compact benchtop instrument, streamlining molecular workflows. Featuring one of the largest assay menus currently available, the platform supports both high-plex and low-plex PCR testing across genitourinary, gastrointestinal, respiratory, hospital-acquired, and other infectious disease panels. Delivering results in as little as 30 minutes, Vivalytic enables laboratories to increase efficiency while supporting faster clinical decision-making.
Also featured was the Acusera Smart Controls range, a third-party quality-control solution designed to simplify QC management. By eliminating manual preparation steps and consolidating multiple controls into a single format, these controls help optimize workflows, reduce hands-on time, and minimize waste associated with dead volume. The portfolio includes controls for clinical chemistry, immunoassays, liquid cardiac markers, and parathyroid hormone (PTH) testing.
In addition, Randox presented its External Quality Assessment (EQA) programs. The Randox International Quality Assessment Scheme (RIQAS) is the world’s largest EQA program, supporting more than 85,000 laboratory participants across over 145 countries. RIQAS enables laboratories to assess and enhance analytical performance by benchmarking results against international peer groups using comparable methods and instrumentation.
Beyond its product showcase, Randox hosted educational sessions at its booth that facilitated in-depth discussions with clinical laboratory professionals and industry leaders. On the opening day, Ibrahim Mansoor, MD, FCAP, FIAC, delivered a session on the emerging threat of Candida auris, discussing its association with climate-driven fungal adaptation and the spread of thermotolerant pathogens. He reviewed its epidemiology, from early reports to global outbreaks that have reshaped infection control, with particular attention to growing impact in the Middle East. The session highlighted diagnostic challenges, antifungal resistance, and the need for stronger screening and preparedness.
On the second day of the event, Anil Padmanabhan showcased how the Evidence MultiSTAT Analyser advances precision medicine through near-patient multiplex biomarker testing. He highlighted its role in guiding decisions in CAR-T hyperinflammation, kidney dysfunction, ARDS phenotyping, and prostate cancer risk stratification, along with the world-first CE-IVD–marked Genetic Risk Score test for Type 1 Diabetes. The session underscored how biochip array technology is accelerating actionable, early diagnostics.
Related Links:
Randox
